ENDRA Life Sciences (NDRA) Set to Announce Quarterly Earnings on Thursday

ENDRA Life Sciences (NASDAQ:NDRAGet Rating) is scheduled to be releasing its earnings data after the market closes on Thursday, May 12th. Analysts expect ENDRA Life Sciences to post earnings of ($0.07) per share for the quarter. Persons that are interested in registering for the company’s earnings conference call can do so using this link.

ENDRA Life Sciences (NASDAQ:NDRAGet Rating) last announced its earnings results on Wednesday, March 30th. The company reported ($0.07) EPS for the quarter. During the same quarter last year, the company posted ($0.10) earnings per share.

ENDRA Life Sciences stock opened at $0.27 on Thursday. The stock has a market capitalization of $11.86 million, a price-to-earnings ratio of -1.00 and a beta of 1.40. ENDRA Life Sciences has a 52-week low of $0.22 and a 52-week high of $2.44. The stock’s 50 day moving average price is $0.35 and its two-hundred day moving average price is $0.69.

Several institutional investors and hedge funds have recently modified their holdings of the stock. Geode Capital Management LLC lifted its holdings in shares of ENDRA Life Sciences by 2.3% in the 3rd quarter. Geode Capital Management LLC now owns 323,679 shares of the company’s stock worth $559,000 after purchasing an additional 7,197 shares in the last quarter. Royal Bank of Canada lifted its holdings in shares of ENDRA Life Sciences by 65.3% in the 2nd quarter. Royal Bank of Canada now owns 25,310 shares of the company’s stock worth $55,000 after purchasing an additional 10,000 shares in the last quarter. Morgan Stanley lifted its holdings in shares of ENDRA Life Sciences by 5.3% in the 2nd quarter. Morgan Stanley now owns 232,312 shares of the company’s stock worth $506,000 after purchasing an additional 11,678 shares in the last quarter. Citadel Advisors LLC bought a new position in shares of ENDRA Life Sciences in the 3rd quarter worth $26,000. Finally, Virtu Financial LLC bought a new position in shares of ENDRA Life Sciences in the 4th quarter worth $50,000. Institutional investors own 10.03% of the company’s stock.

NDRA has been the topic of a number of research analyst reports. HC Wainwright cut their price target on ENDRA Life Sciences from $6.00 to $5.00 and set a “buy” rating on the stock in a report on Thursday, April 7th. Zacks Investment Research upgraded ENDRA Life Sciences from a “sell” rating to a “hold” rating in a report on Wednesday.

About ENDRA Life Sciences (Get Rating)

ENDRA Life Sciences Inc develops technology for improving the capabilities of clinical diagnostic ultrasound. The company develops thermo-acoustic enhanced ultrasound technology that transmits sound waves, which bounce off tissues, organs, and blood in the body for use in the treatment of nonalcoholic fatty liver disease, as well as in temperature monitoring of thermoablative surgery, vascular imaging, and tissue perfusion.

See Also

Earnings History for ENDRA Life Sciences (NASDAQ:NDRA)

Receive News & Ratings for ENDRA Life Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ENDRA Life Sciences and related companies with MarketBeat.com's FREE daily email newsletter.